What is CORUS: Activity-Based Costing?

The CORUS Suite: Activity-Based Costing application leverages the DOS™ platform and activity-based costing to deliver accurate and actionable data. The CORUS: Costing application helps users manage the true cost of care across the continuum.

Our Approach

Based on more granular data like EMR, claims, payroll, and more, CORUS: Activity-Based Costing uses activities—not just RVUs—to deliver an accurate, comprehensive view of all your costs and guides your cost accountants through the costing and validation process.

Watch a 3-minute video overview
Activity-Based Costing Benefits & Features

Faster, more streamlined processes save time and reduce errors.

The CORUS: Costing interface guides the finance team through the costing process—including validation—to save time and reduce errors.

Transparency into your costs.

Integrated and aggregated data from your EMR, clinical, financial (claims, GL, payroll, supply chain, etc.), patient satisfaction, operation, and other data sources enable you to identify actionable insights into the real drivers of cost variation.

Costing data shared with the masses.

With costing data readily available, analysts can more quickly respond to financial questions and problems reported by the organization and leadership.

Trend, compare, and validate your costs.

Using embedded reporting, you can view trending charges, payments, and other data points; compare costs between service lines, specialties, etc.; and validate your costing to ensure accuracy.

Client Testimonials

“This solution’s tabular reporting and capability for easy interfacing are amazing. Our old product didn’t get to the same level of detail that CORUS does. CORUS has provided us with a completely different approach for how we define costs and link them to activity It is a completely different tool.”

VP/Other Executive KLAS Interview, October 2020

“The transition from our old product to CORUS has been huge. This transition is going to be a lot of work for us. I am in the honeymoon phase, and probably will be until we start getting things into our analysts’ hands. We will definitely have to work with them to get them comfortable with CORUS. Overall, CORUS is going to allow us to redefine cost and activity. This solution will be much easier for our operational leaders and physicians to understand. Previously, there was always a barrier between us and the operational folks. There was an extra step of translation where we would end up losing things. Everything was vague. CORUS will allow us to completely change the narrative and help us give folks the ability to work with their own data to identify variation and opportunities.”

VP/Other Executive KLAS Interview, October 2020

“CORUS is almost like an enterprise data warehouse. The end product is kind of like a costing platform. We need to have our volume, GL information, and patient-level information. Then, we can match all those things together to come up with a patient-level cost. This is nice because there is a lot of underlying data in CORUS that lets us do really sophisticated things in a quick and accurate manner. The data sits in one central repository. This has allowed us to make some pretty great things for monitoring and understanding readmission costs for different populations. We have access to a lot of great data. This solution is pretty powerful.”

Director KLAS Interview, October 2020

“I would recommend CORUS to others. I know more folks would like this system, and I feel like we could learn a lot from other customers. For me, CORUS is an industry changer. I think one weakness of Health Catalyst is that few folks have CORUS implemented. There isn’t a huge user group for us to collaborate with. Even outside of wanting to get more people involved with the solution, I would still recommend CORUS because of how easily it can get an organization’s costs and activity and report on them. This solution is a game changer, not just for finance, but for an entire organization. Organizations want clean data, and that is what CORUS provides.”

VP/Other Executive KLAS Interview, October 2020